Dr Reddy's Laboratories

'India began drug discovery before China, but China has moved years ahead'

India's pharma industry must pivot from global leadership in generics to innovation, backed by stronger policy, R&D funding and regulatory reforms, says Satish Reddy

Dr Reddy's may underperform on growth, margin worries after muted Q1

North America weakness, lower margins, uncertainty over key launches weigh on earnings outlook

Dr Reddy's Labs Q1FY27 results: Net profit plunges 69% to ₹443 crore

The drugmaker attributed the sharp earnings decline to a one-time semaglutide provision and the end of its lenalidomide agreement, while retaining its FY27 guidance

Glenmark, Biocon, Aurobindo slip 3% on Trump's generic drug tariff plan

The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.

Dr Reddy's Foundation targets 100k soil samples ahead of rabi season

Dr Reddy's Foundation -- a family-owned trust and one of the key beneficiaries of the CSR funds of pharma major Dr Reddy's Laboratories -- is scaling up operations at its Hyderabad soil testing facility with the lab targeting between 75,000 and 1,00,000 samples ahead of the next Rabi season -- more than double what it processed in its first full year of operations. The move comes amid growing concern over depleting soil health and implementation gaps in the Centre's Soil Health Card scheme rolled out nationally in 2015. "Though the government's soil testing ecosystem exists, the scale of the problem is huge. So we decided to address this issue in our own way," said Suman Saraswathibatla, Director (Rural Livelihoods and Climate Action) at the foundation. This soil testing facility is central to the Foundation's broader soil health and regenerative agriculture programme, under which assessing soil condition is treated as the starting point for any intervention. The push for an in-hou

Dr Reddy's drops 4% on semaglutide setback; should investors buy the dip?

The company said certain batches of semaglutide were found to be out of specification due to issues associated with the API used in the product

Dr Reddy's to miss annual semaglutide supply target over API quality issue

Drugmaker says it will supply 6-7 million pens in the last two quarters of FY27 and restart production by November after resolving the API-related quality issue

DRL gets 7 observations after USFDA inspection of Hyderabad biologics plant

USFDA completed a pre-license inspection of the Hyderabad facility and issued a Form 483 with seven observations, which the company said it will address within the stipulated timeline

Dr Reddy's unveils oral diabetes drug Obeda for type 2 patients in India

The once-daily prescription tablet for type 2 diabetes received CDSCO approval after a Phase III trial showed comparable efficacy and safety to the innovator drug

Biosimilars could surpass generics in US mkt by early 2030s: Dr Reddy's CEO

Dr Reddy's CEO Erez Israeli says semaglutide, biosimilars and oncology will drive the company's next growth phase as it expands beyond traditional generics globally

Dr Reddy's Laboratories launches generic Semaglutide injection in Canada

Dr Reddy's Laboratories on Saturday said it has launched its generic version of Semaglutide injection used in treatment of type 2 diabetes in Canada. The company is among the first firms to introduce a generic Semaglutide injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on April 28, 2026, Dr Reddy's said in a statement. Canada is the first G7 country to grant market authorisation for Semaglutide injection, it added. "The milestone highlights our readiness to serve the Canadian patients, supported by our deep expertise in complex drug and peptide development," Dr Reddy's CEO Erez Israeli said. He further said:"With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients." The Canada launch builds on the momentum of the company's recent launch in India under the brand name Obeda, Israeli said. "As GLP-1

Dr Reddy's Q4 PAT crashes 86% on generic Revlimid shock in US market

The fall was driven by weak US sales of Revlimid, offset only partially by growth in India, Europe, and emerging markets

Dr Reddy's Q4 results: PAT down 86% at ₹221 crore, revenue drops 11.51%

Drugmaker Dr Reddy's Laboratories Ltd on Tuesday reported an 86 per cent dip in consolidated profit after tax at Rs 221.3 crore in the fourth quarter ended March 31, 2026 hit by lower generics sales in North America. The company had posted a profit after tax of Rs 1,586.7 crore in the corresponding quarter previous fiscal year, Dr Reddy's Laboratories Ltd said in a regulatory filing. Consolidated total revenue from operations in the fourth quarter stood at Rs 7,546.4 crore as against Rs 8,528.4 crore in the same period a year ago, it added. Revenue from generic drugs in North America in the quarter was down 51 per cent at Rs 1,756.2 crore as compared to Rs 3,558.6 crore in the year-ago period. On the other hand generics revenue in India grew 20 per cent at Rs 1,566.3 crore as compared to Rs 1,304.7 crore in the corresponding period a year ago, the company said. Similarly, generics revenue in Europe grew by 14 per cent to Rs 1,452 crore from Rs 1,275 crore in the year ago period.

Q4 results: Dr Reddy's, Tata Power, Pfizer, Kalpataru among 104 on May 12

Q4FY26 company results: Firms including Berger Paints, Torrent Power, Max Financial Services, Nazara Technologies, and Vinati Organics are also to release their January-March earnings today

Dr Reddy's Q4 preview: Lower US sales to drag earnings; profit may dip 34%

Dr Reddy's net profit is expected to come at ₹1,035 crore, marking a moderate 34 per cent Y-o-Y decrease, on average, as against ₹1,587 crore in the Q4FY25

Nifty Pharma index soars 3%; Dr Reddy's, Piramal Pharma rally up to 9%

Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.

Pharma cos brace for soft Q4; US drag persists; domestic growth cushions

Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements

10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Dr Reddy's enters semaglutide market, launches diabetes generic drug

Drugmaker expects to receive regulatory approval for weightloss sema generic in a few months

Analyst suggests Nifty strategy; bets on Oil India, Dr Reddy's Labs

Ajit Mishra of Religare Broking recommends Nifty strategy and two stocks to buy; check details here